Title : Anatoxin-a-evoked [3H]dopamine release from rat striatal synaptosomes - Soliakov_1995_Neuropharmacol_34_1535 |
Author(s) : Soliakov L , Gallagher T , Wonnacott S |
Ref : Neuropharmacology , 34 :1535 , 1995 |
Abstract :
Presynaptic nicotinic acetylcholine receptors on striatal nerve terminals modulate the release of dopamine. Using rat striatal synaptosomes loaded with [3H]dopamine, we have characterized the action of the selective nicotinic agonist, (+/-)anatoxin-a, with respect to [3H]dopamine release, in order to explore the mechanisms coupling nicotinic receptor activation to exocytosis. Anatoxin-a evoked [3H]dopamine release in a concentration-dependent and mecamylamine-sensitive manner, EC50 = 0.11 microM. The maximum [3H]dopamine release elicited by anatoxin-a was only 20% of the maximum elicited by KCl depolarization; there was no additivity between anatoxin-a and sub-maximal concentrations of KCl. Both agents stimulated Ca(2+)-dependent release that was equally sensitive to inhibition by 200 microM Cd2+. This result suggests that anatoxin-a-stimulated exocytosis is mediated by Ca2+ influx via voltage-sensitive Ca2+ channels, with little contribution from Ca2+ entering directly through the nicotinic receptor channel. This view is supported by the abolition of anatoxin-a-evoked [3H]dopamine release in Na(+)-depleted medium. A partial (40%) inhibition by tetrodotoxin was observed. These data suggest that activation of presynaptic nicotinic acetylcholine receptors by anatoxin-a results in an influx of Na+, producing sufficient local depolarization to open voltage-sensitive Ca2+ and Na+ channels. The latter may then amplify the response, activating further Ca2+ channels. The particular voltage-sensitive Ca2+ channels involved remain to be determined. |
PubMedSearch : Soliakov_1995_Neuropharmacol_34_1535 |
PubMedID: 8606800 |
Soliakov L, Gallagher T, Wonnacott S (1995)
Anatoxin-a-evoked [3H]dopamine release from rat striatal synaptosomes
Neuropharmacology
34 :1535
Soliakov L, Gallagher T, Wonnacott S (1995)
Neuropharmacology
34 :1535